Table 1.
Age and sex of the participants included in the study according to the vaccine administered as third dose and SARS-CoV-2 nucleocapsid IgG test results
| Age |
p valuea | Sex |
p valuea | ||||
|---|---|---|---|---|---|---|---|
| 18–49 | 50–59 | Female | Male | ||||
| NC- | |||||||
| BNT162b2 | 6 (54.5%) | 5 (45.5%) | 6 (54.5%) | 5 (45.5%) | |||
| mRNA-1273 | 3 (30%) | 7 (70%) | 0.387 | 4 (40%) | 6 (60%) | 0.670 | |
| NC+ | |||||||
| BNT162b2 | 8 (44.4%) | 10 (55.6%) | 7 (38.9%) | 11 (61.1%) | |||
| mRNA-1273 | 8 (72.7%) | 3 (27.3%) | 0.249 | 8 (72.7%) | 3 (27.3%) | 0.128 | |
a
According to Fisher's exact test and comparing BNT162b2 and mRNA-1273 arms.